[{"orgOrder":0,"company":"Helix BioPharma","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Termination","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"Helix BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Helix BioPharma \/ Helix BioPharma","highestDevelopmentStatusID":"10","companyTruncated":"Helix BioPharma \/ Helix BioPharma"},{"orgOrder":0,"company":"Helix BioPharma","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"Helix BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Helix BioPharma \/ Helix BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Helix BioPharma \/ Helix BioPharma"},{"orgOrder":0,"company":"Helix BioPharma","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"L-DOS47","moa":"Vascular endothelial growth factor receptor 2 (KDR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helix BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helix BioPharma \/ Helix BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"Helix BioPharma \/ Helix BioPharma"},{"orgOrder":0,"company":"Helix BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Vascular endothelial growth factor receptor 2 (KDR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helix BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helix BioPharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Helix BioPharma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Helix BioPharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : MoonLake plans to execute on its development program to unlock the potential of Sonelokimab, the novel investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients with inflammatory diseases.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          May 04, 2022

                          Lead Product(s) : Sonelokimab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Recipient : MoonLake Immunotherapeutics

                          Deal Size : Undisclosed

                          Deal Type : Termination

                          blank

                          02

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Proceeds from the transaction are expected to provide MoonLake with the capital needed to accelerate the development of the clinical stage, tri-specific Nanobody® sonelokimab, in multiple inflammatory diseases in dermatology and rheumatology driven by I...

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : $230.0 million

                          April 10, 2021

                          Lead Product(s) : Sonelokimab

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Recipient : MoonLake Immunotherapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : In this next stage, the Company together with Moffit, intends to build on these early successes and provide additional preclinical support in using L-DOS47 with immunotherapies as clinical support.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          December 08, 2020

                          Lead Product(s) : L-DOS47

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Moffitt Cancer Center

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Topline data of the recently completed L-DOS47 dose escalation study in combination with pemetrexed and carboplatin in recurrent or metastatic non-squamous non-small cell lung cancer will be published at the ASCO 2020 Annual Conference.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          May 14, 2020

                          Lead Product(s) : L-DOS47,Carboplatin,Pemetrexed

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          December 18, 2019

                          Lead Product(s) : L-DOS47

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Theradex

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          March 26, 2019

                          Lead Product(s) : L-DOS47

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : KCR

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          January 16, 2015

                          Lead Product(s) : L-DOS47

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Pharm-Olam

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          December 05, 2014

                          Lead Product(s) : L-DOS47

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Theradex

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank